Comment on 'anti-adhesion therapies and the rule of 3 for rare events'

Am J Gastroenterol. 2014 Jul;109(7):1083-4. doi: 10.1038/ajg.2014.117.

Authors

Brian G Feagan¹, Jean-Frederic Colombel², Stephen B Hanauer³, Asit Parikh⁴, Paul Rutgeerts⁵, William J Sandborn⁶, Bruce E Sands²

Affiliations

¹ Robarts Clinical Trials Inc., London, Ontario, Canada.
² Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁴ Takeda Pharmaceuticals Inc., Deerfield, Illinois, USA.
⁵ University Hospitals Leuven, Leuven, Belgium.
⁶ University of San Diego California, La Jolla, California, USA.

PMID: 24989100
DOI: 10.1038/ajg.2014.117

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Cell Migration Inhibition / drug effects*
Crohn Disease / drug therapy*
Humans
Leukoencephalopathy, Progressive Multifocal / chemically induced*

Substances

Antibodies, Monoclonal, Humanized